Recovery Expectations After Inspire Hypoglossal Nerve Stimulator Implantation

While not a guarantee for an individual’s experience, this description may inform you on the usual recovery timeline after Inspire implantation.

Recovery after Inspire hypoglossal nerve stimulator (HNS) implantation is generally well-tolerated, with most patients discharged on postoperative day 1 and returning to daily activities within about a week. [1-2] The procedure preserves natural airway anatomy and is significantly less painful than traditional soft tissue or skeletal OSA surgeries, with opioids often unnecessary. [3] Below is a patient-oriented timeline of what to expect.

Immediate Postoperative Period (Days 1–7)

Patients typically go home the day after surgery. There are three incision sites: one below the jaw (submandibular), one on the upper chest (for the neurostimulator/generator), and one lower on the chest wall (for the respiratory sensing lead). [2] Mild to moderate soreness at these sites is expected. The most common early complaint is pain (reported in ~20–35% of patients across databases), along with tongue or oral discomfort, which is usually temporary and resolves within weeks. [1][4-5] Sutures are generally removed at approximately one week, at which point patients are cleared to resume activities of daily living. [2] Hematoma or seroma at the incision sites occurs in roughly 10% of reported adverse events. [4]

Weeks 2–4: Healing Phase

During this period, the device remains turned off to allow tissue healing. [2][6] Patients should avoid strenuous upper extremity movements for the first month to prevent lead displacement or device migration. [2] Some patients report a sensation of tightness or awareness of the leads tunneled under the skin in the neck and chest, and a small number experience lead tethering symptoms. [5] Swelling and mild discomfort at the generator pocket site on the chest gradually resolve.

Month 1: Device Activation

At approximately one month postoperatively, the device is activated during an outpatient clinic visit. [6-8] The clinician determines the sensation and functional voltage threshold — the level at which the tongue protrudes beyond the lower teeth comfortably. [9] Patients are given a handheld remote control to turn the device on at bedtime and off in the morning. The stimulation produces a gentle, rhythmic tongue protrusion sensation that patients must acclimate to. A 30-minute start delay is typically programmed so the patient can fall asleep before stimulation begins. Some patients initially experience stimulation discomfort (reported in ~14% of social media posts and as a common early complaint), which usually improves with acclimatization and voltage adjustment. [5][10]

Months 2–3: Titration and Optimization

An in-laboratory polysomnography (sleep study) is performed around 2 months postoperatively to titrate the device — adjusting voltage, electrode configuration, and timing to optimally reduce apnea events while minimizing arousals. [7-8] Fewer than one-third of patients require additional device reconfiguration for complaints such as perceived stimulus discomfort, frequent awakenings, or persistent fatigue. [11] Patient-reported outcomes improve rapidly: within just one month of activation, significant reductions in daytime sleepiness (ESS), insomnia severity, and depressive symptoms are observed, even before optimal titration. [12]

Long-Term Experience (Months 3–12+)

By 3–6 months, most patients have fully acclimated to the device. Average nightly usage is approximately 5.6 hours per night (39 hours/week), reflecting high adherence. [13] At 12 months, the Inspire device reduces AHI by approximately 20 events/hour, with ESS scores decreasing by ~5 points and FOSQ scores improving by ~3.5 points. [14] At 48 months, 85% of bed partners report soft to no snoring. [15] Five-year STAR trial data demonstrate durable improvements, with normalization of sleepiness scores increasing from 33% to 78% and quality-of-life normalization from 15% to 67%. [16]

Uncommon but Notable Complications

Rates of device explant and revision within the first year are low at 0.7% and 1.5%, respectively. [17] Infection is the most common reason for explant (0.4%), and surgical correction is the most common reason for revision (0.7%). [17] Rare complications include pneumothorax from sensing lead placement, lip weakness (~7% in patient-reported social media data vs. <1% in formal databases), and tongue abrasions from chronic stimulation. [4-5][10] The 5-year device survival probability is approximately 98.3%. [10]

References:

1.Evaluation of Upper Airway Stimulation for Adolescents With Down Syndrome and Obstructive Sleep Apnea.

JAMA Otolaryngology-- Head & Neck Surgery. 2022. Yu PK, Stenerson M, Ishman SL, et al.

2. Hypoglossal Nerve Stimulator.

Journal of Medical Insight (JOMI). 2023. Russel Kahmke, MD, Adam Honeybrook, Clayton Wyland, C. Scott Brown, MD

3. Perioperative Care of Patients With Obstructive Sleep Apnea Undergoing Upper Airway Surgery.

JAMA Otolaryngology-- Head & Neck Surgery. 2019. Ravesloot MJL, de Raaff CAL, van de Beek MJ, et al.

4. Comprehensive Analysis of Adverse Events Associated With Hypoglossal Nerve Stimulators: Insights From the MAUDE Database.

Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2024. Bentan MA, Nord R.

5. Are There Hidden Adverse Events in Hypoglossal Nerve Stimulation: Comparing Social Media and a Federal Database.

The Laryngoscope. 2024. Bentan MA, Dawood E, Moffatt D, Suurna MV, Nord R.

6. Upper-Airway Stimulation for Obstructive Sleep Apnea.

The New England Journal of Medicine. 2014. Strollo PJ, Soose RJ, Maurer JT, et al.RCT

7. Evaluation of Hypoglossal Nerve Stimulation Treatment in Obstructive Sleep Apnea.

JAMA Otolaryngology-- Head & Neck Surgery. 2019. Kent DT, Carden KA, Wang L, Lindsell CJ, Ishman SL.

8. Hypoglossal Nerve Stimulation on Sleep and Level of Alertness in OSA: A Preliminary Study.

Neurology. 2018. Philip P, Heiser C, Bioulac S, et al.

9. Titration Protocol for Upper Airway Stimulation in Pediatric Patients With Down Syndrome.

JAMA Otolaryngology-- Head & Neck Surgery. 2025. Frederick RM, Baldassari CM.Clinical Trial

10. Adverse Events With Hypoglossal Nerve Stimulation in the Treatment of Obstructive Sleep Apnea-a Systematic Review of Clinical Trials and Real-World Data.

Journal of Clinical Medicine. 2024. Wollny M, Heiser C, Sommer U, Schöbel C, Braun M.Review

11. Reconfiguration of Upper Airway Stimulation Devices Utilizing Awake Endoscopy.

The Laryngoscope. 2020. Meleca JB, Kominsky AH.

12. Association of Hypoglossal Nerve Stimulation With Improvements in Long-term, Patient-Reported Outcomes and Comparison With Positive Airway Pressure for Patients With Obstructive Sleep Apnea.

JAMA Otolaryngology-- Head & Neck Surgery. 2022. Pascoe M, Wang L, Aylor J, et al.

13. Outcome After One Year of Upper Airway Stimulation for Obstructive Sleep Apnea in a Multicenter German Post-Market Study.

The Laryngoscope. 2018. Steffen A, Sommer JU, Hofauer B, et al.Clinical Trial

14. Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea in Adults: An Updated Systematic Review and Meta-Analysis.

Respiratory Medicine. 2024. Alrubasy WA, Abuawwad MT, Taha MJJ, et al.SR

15. Upper Airway Stimulation for Obstructive Sleep Apnea: Patient-Reported Outcomes After 48 Months of Follow-Up.

Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2017. Gillespie MB, Soose RJ, Woodson BT, et al.

16. Upper Airway Stimulation for Obstructive Sleep Apnea: 5-Year Outcomes.

Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery. 2018. Woodson BT, Strohl KP, Soose RJ, et al.Clinical Trial

17. Device-Related Outcomes Following Hypoglossal Nerve Stimulator Implantation.

Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine. 2024. Moroco AE, Wei Z, Byrd I, et al.